<code id='DB77FAD0ED'></code><style id='DB77FAD0ED'></style>
    • <acronym id='DB77FAD0ED'></acronym>
      <center id='DB77FAD0ED'><center id='DB77FAD0ED'><tfoot id='DB77FAD0ED'></tfoot></center><abbr id='DB77FAD0ED'><dir id='DB77FAD0ED'><tfoot id='DB77FAD0ED'></tfoot><noframes id='DB77FAD0ED'>

    • <optgroup id='DB77FAD0ED'><strike id='DB77FAD0ED'><sup id='DB77FAD0ED'></sup></strike><code id='DB77FAD0ED'></code></optgroup>
        1. <b id='DB77FAD0ED'><label id='DB77FAD0ED'><select id='DB77FAD0ED'><dt id='DB77FAD0ED'><span id='DB77FAD0ED'></span></dt></select></label></b><u id='DB77FAD0ED'></u>
          <i id='DB77FAD0ED'><strike id='DB77FAD0ED'><tt id='DB77FAD0ED'><pre id='DB77FAD0ED'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:66666
          Judge's gavel
          Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

          WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

          Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

          advertisement

          Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more
          Three trends to watch in biotech in 2024
          Three trends to watch in biotech in 2024

          ChristineKao/STATEverywinter,likePunxsutawneynobles,biotech’smanythoughtleadersgatherfortheJ.P.Morga

          read more
          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more

          Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

          CraigF.Walker/TheBostonGlobeMaryBrownwassippingcoffeeathomeinOntario,Calif.,Sundaymorningwhenafriend